.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
This phase 4 randomized, double-blind, placebo-controlled trial assessed a single 75-mg dose of rimegepant in adults with migraine who were unsuitable for triptans because of intolerance, inadequate efficacy or contraindications. A total of 585 participants received treatment, with 570 included in the efficacy analysis. At two hours after dosing, migraine pain relief occurred in 55.9% of participants receiving rimegepant compared with 32.7% receiving placebo, an absolute difference of 23.2 percentage points (95% CI, 15.3–31.1; \(p<0.0001\)). Rimegepant was also superior across all 10 key secondary endpoints, including pain freedom and functional recovery. Adverse-event rates were similar between groups (12.5% versus 12.1%), and no severe or serious adverse events were reported in the rimegepant group. The results support rimegepant as an acute treatment option for patients who cannot use triptans.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
This phase 4 randomized, double-blind, placebo-controlled trial assessed a single 75-mg dose of rimegepant in adults with migraine who were unsuitable for triptans because of intolerance, inadequate efficacy or contraindications. A total of 585 participants received treatment, with 570 included in the efficacy analysis. At two hours after dosing, migraine pain relief occurred in 55.9% of participants receiving rimegepant compared with 32.7% receiving placebo, an absolute difference of 23.2 percentage points (95% CI, 15.3–31.1; \(p<0.0001\)). Rimegepant was also superior across all 10 key secondary endpoints, including pain freedom and functional recovery. Adverse-event rates were similar between groups (12.5% versus 12.1%), and no severe or serious adverse events were reported in the rimegepant group. The results support rimegepant as an acute treatment option for patients who cannot use triptans.
Today
A 60-year-old woman presented with subacute cerebellar ataxia, dysautonomia, and hyperreflexia. Despite negative commercial antibody panels, tissue-based assays and phenotypic evolution to blepharospasm guided diagnostic resolution through specialized neuroimmunology testing.
Today
A prospective study reveals significant first-trimester trace-element alterations in pregnant women with epilepsy. Lower serum selenium independently predicted subsequent seizure recurrence despite prior remission, highlighting the vital clinical role of micronutrient profiling during antenatal care.
Today
A 15-year-old patient presented with knee arthralgia and acute rheumatic fever, exhibiting complex arrhythmias including AV blocks and non-sustained ventricular tachycardia despite lacking severe valvulitis. This highlights the importance of extended Holter monitoring in pediatric rheumatic carditis.
Today
An eight-year longitudinal imaging follow-up reveals severe temporomandibular joint remodeling in nodulosis-arthropathy-osteolysis (NAO) syndrome. Despite extensive osseous destruction, the patient maintained functional jaw opening without TMJ interventions, highlighting the role of conservative management.
Today
Discover essential clinical insights into AGLP1-type amyloidosis, a rare localized complication of glucagon-like peptide-1 analog injections. Learn how histopathology and mass spectrometry differentiate benign iatrogenic amyloidomas from systemic disease, preventing misdiagnosis and unwarranted therapies.
Today
